What Happened: SACHS's recent move, as outlined in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday, involves purchasing 5,000 shares of Vertex Pharmaceuticals. The total ...

Even with the S&P 500 near an all-time high, there are plenty of compelling growth, dividend, and value stocks to buy now.

Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, secures a spot on Fortune's 2025 list of the 100 Most ...

NEW YORK, NY-Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, has been named one of the 100 Most Powerful ...

The postoperative pain management market is witnessing steady growth, driven by the rising number of surgical procedures globally and increasing awar ...

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex's late-stage pipeline also gives investors several lottery tickets with great odds. The drugmaker is evaluating ...

Vertex Pharmaceuticals recently reported a significant revenue jump to $2,965 million in Q2 2025. Despite this success, the ...

Shantanu Narayen, Reshma Kewalramani, Neal Mohan, Mukesh Ambani and Gautam Adani also make the Fortune 100 Most Powerful ...

Kewalramani, CEO of Vertex Pharmaceuticals, joins Fortune's 100 Most Powerful People in Business. Ranked 62nd, she is the 1st ...

Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.